Cardiovascular Risk and MASLD – Integrating Lipid Management with Novel Agents
Pablo Corral, Past President of Argentine Lipid Society, has shared a post on X:
“Understanding MASLD, from molecular pathogenesis to cardiovascular risk.
A concise review for the clinical cardiologist.
MASLD not only drives liver injury but also worsens lipid metabolism, fueling atherogenic dyslipidemia. Increased VLDL, small dense LDL, dysfunctional HDL.
The review in ATH journal highlights that.
•Statins are both safe and effective in MASLD, yet underprescribed.
•Ezetimibe and pemafibrate may improve lipid profile and hepatic parameters.
•GLP-1RAs and SGLT2i show dual benefit on liver fat, cardiometabolic risk, and CVD outcomes.
•Emerging agents (resmetirom, lanifibranor) target both hepatic fibrosis and lipid metabolism.
Lipid-lowering therapy remains central in MASLD management, but must be integrated with newer agents for optimal cardio-hepatic protection .”
Read more here.
Stay informed with Hemostasis Today.
-
Apr 12, 2026, 22:12Maciej Banach: The ‘Metastatic’ Cardiovascular Threat We Can No Longer Ignore
-
Apr 12, 2026, 21:52Umar Jawed: The Most Dangerous Anti-D Result Is Not the Highest One – It’s the One You Underestimate Early
-
Apr 12, 2026, 21:37Demosthenes Panagiotakos: Hellenic Atherosclerosis Society Calls for Papers on Innovative Strategies in Atherosclerotic Plaque Management
-
Apr 12, 2026, 21:24Heghine Khachatryan: Diagnosing PNH in Resource-Limited Settings
-
Apr 12, 2026, 21:15Katariina Öörni: Role of Cholesterol Absorption Efficiency in Atherosclerosis
-
Apr 12, 2026, 17:34Caitlin Raymond: Granulocyte Transfusions for the Overworked Fellow
-
Apr 12, 2026, 17:33Augustina Isioma Ikusemoro: ABO Typing Is Not the Same in Infants and Adults
-
Apr 12, 2026, 17:32Bastu Odoka: Same Blood Group Does Not Guarantee Compatibility
-
Apr 12, 2026, 17:31Jack Hadfield: SARS-CoV-2–Associated Lasting Mitochondrial Injury in Cardiomyocytes